RT Journal Article
T1 The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.
A1 Arias de la Rosa, Ivan
A1 Lopez-Montilla, Maria Dolores
A1 Roman-Rodriguez, Cristobal
A1 Perez-Sanchez, Carlos
A1 Gomez-Garcia, Ignacio
A1 Lopez-Medina, Clementina
A1 Ladehesa-Pineda, Maria Lourdes
A1 Abalos-Aguilera, Maria Del Carmen
A1 Ruiz, Desiree
A1 Patiño-Trives, Alejandra Maria
A1 Luque-Tevar, Maria
A1 Añon-Oñate, Isabel
A1 Perez-Galan, Maria Jose
A1 Guzman-Ruiz, Rocio
A1 Malagon, Maria M
A1 Lopez-Pedrera, Chary
A1 Escudero-Contreras, Alejandro
A1 Collantes-Estevez, Eduardo
A1 Barbarroja, Nuria
K1 Apremilast
K1 Cardiometabolic profile
K1 Cardiovascular risk
K1 Insulin resistance
K1 Methotrexate
K1 Obesity and disease activity
K1 Psoriatic arthritis
AB (1) To evaluate clinical and molecular cardiovascular disease (CVD) signs and their relationship with psoriatic arthritis (PsA) features and (2) to identify a clinical patient profile susceptible to benefit from methotrexate (MTX) and/or apremilast regarding CVD risk. This cross-sectional study included 100 patients with PsA and 100 age-matched healthy donors. In addition, an exploratory cohort of 45 biologically naïve patients treated for 6 months with apremilast, MTX or combined therapy according to routine clinical practice was recruited. Extensive clinical and metabolic profiles were obtained. Ninety-nine surrogate CVD-related molecules were analysed in plasma and peripheral blood mononuclear cells (PBMCs). Hard cluster analysis was performed to identify the clinical and molecular phenotypes. Mechanistic studies were performed on adipocytes. Cardiometabolic comorbidities were associated with disease activity and long-term inflammatory status. Thirty-five CVD-related proteins were altered in the plasma and PBMCs of PsA patients and were associated with the key clinical features of the disease. Plasma levels of some of the CVD-related molecules might distinguish insulin-resistant patients (MMP-3, CD163, FABP-4), high disease activity (GAL-3 and FABP-4) and poor therapy outcomes (CD-163, LTBR and CNTN-1). Hard cluster analysis identified two phenotypes of patients according to the rates of cardiometabolic comorbidities with distinctive clinical and molecular responses to each treatment. (1) Novel CVD-related proteins associated with clinical features could be emerging therapeutic targets in the context of PsA and (2) the pleiotropic action of apremilast could make it an excellent choice for the management of PsA patients with high CVD risk, targeting metabolic alterations and CVD-related molecules.
PB Wiley-Blackwell Publishing
YR 2022
FD 2022
LK http://hdl.handle.net/10668/19994
UL http://hdl.handle.net/10668/19994
LA en
NO Arias de la Rosa I, López-Montilla MD, Román-Rodríguez C, Pérez-Sánchez C, Gómez-García I, López-Medina C, et al. The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast. J Intern Med. 2022 May;291(5):676-693
DS RISalud
RD Apr 9, 2025